Literature DB >> 17356077

Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis.

Steven D Nathan1, Oksana A Shlobin2, Shahzad Ahmad2, Susan Urbanek2, Scott D Barnett2.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is commonly seen in patients with idiopathic pulmonary fibrosis (IPF). We sought to examine the relationship between pulmonary function tests (PFTs), including the percentage of predicted FVC (FVC%), percentage of predicted total lung capacity, percentage of predicted diffusing capacity of the lung for carbon monoxide (Dlco%), the composite physiologic index (CPI), and PH. The ability of FVC%, Dlco%, and FVC%/Dlco% ratio to predict underlying PH was assessed.
METHODS: Retrospective review of IPF patients seen at a tertiary referral center over an 8-year interval in whom both PFT and right-heart catheterization data were available.
RESULTS: The study cohort consisted of 118 patients, of whom 48 patients (40.7%) had PH. There was no correlation between measures of lung volumes or the CPI with underlying PH. There was a modest association between Dlco% and PH, with Dlco% < 30 having a twofold-higher prevalence of PH (56.4%) compared to Dlco% >/= 30 (28.6%). Cardiac dysfunction might have played a small role, since 16.1% of the patients had an associated elevated pulmonary capillary wedge pressure. There was a trend to a higher prevalence and greater severity of PH in those patients with FVC% > 70 compared to the group with FVC% < 40.
CONCLUSION: PH is common in patients with IPF. There is a poor correlation between lung function measures and PH, suggesting that factors other than fibrosis may play a role in the etiology. The unexpected high prevalence and severity of PH in patients with well-maintained lung function have implications for the prognosis and management of the disease.

Entities:  

Mesh:

Year:  2007        PMID: 17356077     DOI: 10.1378/chest.06-2485

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  48 in total

1.  AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis.

Authors:  Malik Bisserier; Javier Milara; Yassine Abdeldjebbar; Sarah Gubara; Carly Jones; Carlos Bueno-Beti; Elena Chepurko; Erik Kohlbrenner; Michael G Katz; Sima Tarzami; Julio Cortijo; Jane Leopold; Roger J Hajjar; Yassine Sassi; Lahouaria Hadri
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

2.  Cardiac Effect of Interstitial Lung Disease Correlated with Spirometry and Six Minute Walk Test.

Authors:  Mitali Bharat Agrawal; Nilkanth Tukaram Awad
Journal:  J Clin Diagn Res       Date:  2017-02-01

3.  A patient with severe pulmonary hypertension for hip arthroplasty.

Authors:  Michael K Urban; Kethy M Jules-Elysee
Journal:  HSS J       Date:  2014-05-15

4.  Prognostic Significance of Red Cell Distribution Width in Idiopathic Pulmonary Fibrosis and Combined Pulmonary Fibrosis Emphysema.

Authors:  Aslıhan Gürün Kaya; Berna Akıncı Özyürek; Tuğçe Şahin Özdemirel; Miraç Öz; Yurdanur Erdoğan
Journal:  Med Princ Pract       Date:  2020-08-25       Impact factor: 1.927

5.  Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Authors:  D Papakosta; G Pitsiou; Z Daniil; M Dimadi; E Stagaki; A Rapti; K Antoniou; A Tzouvelekis; T Kontakiotis; S Tryfon; V Polychronopoulos; D Bouros
Journal:  Lung       Date:  2011-06-11       Impact factor: 2.584

6.  Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension.

Authors:  Lacedonia Donato; Carpagnano Giovanna Elisiana; Galgano Giuseppe; Schino Pietro; Correale Michele; Natale Daniele Brunetti; Ventura Valentina; Di Biase Matteo; Foschino Barbaro Maria Pia
Journal:  Intern Emerg Med       Date:  2016-11-25       Impact factor: 3.397

Review 7.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

8.  Estimation of pulmonary vascular resistance in patients with pulmonary fibrosis by phase-contrast magnetic resonance imaging.

Authors:  Yuichiro Ayukawa; Sadayuki Murayama; Nanae Tsuchiya; Satomi Yara; Jiro Fujita
Journal:  Jpn J Radiol       Date:  2011-09-17       Impact factor: 2.374

9.  High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Arun S Karlamangla; David J Ross; Michael P Keane; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Jonathan Goldin
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

10.  Iron deposition and increased alveolar septal capillary density in nonfibrotic lung tissue are associated with pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Kyung-Hee Kim; Fabien Maldonado; Jay H Ryu; Patrick W Eiken; Thomas E Hartman; Brian J Bartholmai; Paul A Decker; Eunhee S Yi
Journal:  Respir Res       Date:  2010-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.